Published in Pharma Law Weekly, August 17th, 2004
The small public companies in the "FSB 100" have annual revenue of less than $200 million and a stock price of more than $1. Within that group, the companies are ranked based on earnings growth, revenue growth and stock performance over the past 3 years.
For the first 9 months of fiscal year 2004, Waters net sales were $16.4 million, a 7.8% increase over the same period in 2003. The company sold...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2004-08-17)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.